（一）2020 年公开发行可转换公司债券 经中国证券监督管理委员会证监许可〔2020〕2261 号文核准，并经上海证券交易 所同意，浙江华海药业股份有限公司（以下简称"公司"或"华海药业"）由主承销 商浙商证券股份有限公司（以下简称"浙商证券"）采用向原股东优先配售，原股东 优先配售后余额部分（含原股东放弃优先配售部分）通过网上向社会公众投资者发售 的方式，向社会公开发行可转换公司债券（以下简称"可转债"）1,842.60 万张，每 张面值为人民币 100 元，按面值发行，共募集资金 184,260.00 万元，扣除承销和保荐 费（未包括已预付的 141.51 万元）1,596.79 万元后的募集资金为 182,663.21 万元， 已由主承销商浙商证券于 2020 年 11 月 6 日汇入本公司募集资金监管账户。另减除预 付保荐费、律师费、验资费、资信评级费和发行手续费等与可转债直接相关的外部费 用 492.76 万元后，公司本次募集资金净额为 182,170.45 万元。上述募集资金到位情 况业经天健会计师事务所（特殊普通合伙）（以下简称"天健"）验证，并由其出具 《验资报告》（天健验〔2020〕479 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第九届董事会第四次临时会议于 二零二五年八月二十五日上午九点在公司四楼会议室以通讯方式召开。会议应到会 董事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司董事 长李宏先生主持。会议程序符合《中华人民共和国公司法》（以下简称"公司法"）、 《中华人民共和国证券法》（以下简称"《证券法》"）及《浙江华海药业股份有限公 司章程》（以下简称"公司章程"）的规定。会议审议并通过了如下决议： 一、审议通过了《公司 2025 年半年度报告全文及其摘要》 表决情况：同意：9 票；反对：0 票；弃权：0 票。 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2025-091 号 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 第九届董事会第四次临时会议决议公告 该议案已经公司第九届董事会审计委员会第三次会议审议 ...

浙江华海药业股份有限公司2025 年半年度报告 公司代码：600521 公司简称：华海药业 浙江华海药业股份有限公司 2025 年半年度报告 1 / 198 浙江华海药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人陈保华、主管会计工作负责人张美及会计机构负责人（会计主管人员）周娟声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 公司2025年半年度涉及的经营计划、未来发展战略等前瞻性描述不构成公司对投资者的实质 承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、预测与承诺之间 的差异，敬请广大投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在 ...

每经AI快讯，8月25日，华海药业（600521）公告，为满足全资子公司华海建诚的资金需求，公司决定 为其提供不超过2.05亿元的信用担保，用于向银行申请授信额度。 ...

Group 1 - The core viewpoint of the articles highlights the recent performance and financial metrics of Huahai Pharmaceutical, including stock price movements and trading volumes [1][2] - As of August 22, Huahai Pharmaceutical's stock price increased by 2.05% to 22.39 CNY per share, with a total market capitalization of 33.52 billion CNY [1] - Year-to-date, Huahai Pharmaceutical's stock has risen by 27.06%, with a 5-day increase of 5.36% and a 60-day increase of 30.93% [1] Group 2 - As of March 31, the number of shareholders for Huahai Pharmaceutical increased by 22.34% to 62,700, while the average number of circulating shares per person decreased by 18.26% to 23,402 shares [2] - For the first quarter of 2025, Huahai Pharmaceutical reported a revenue of 2.369 billion CNY, reflecting a year-on-year decrease of 5.21% [2] - The company has distributed a total of 2.989 billion CNY in dividends since its A-share listing, with 1.016 billion CNY distributed over the past three years [2]

Group 1 - The Science and Technology Innovation 50 Index rose over 3%, reaching a new high for the year, driven by a collective surge in chip stocks [1] - Companies such as Jimin Health, Hanzhong Precision Machinery, and Kesen Technology have seen consecutive trading gains, with Jimin Health achieving a five-day streak [1] - The AI server market is dominated by Inspur Information, which holds over 50% market share in China and has reported a 64.39% year-on-year increase in net profit for the first quarter [1] Group 2 - The domestic leading companies are making significant advancements, with Nvidia reportedly developing an AI chip specifically for the Chinese market [3] - Companies like Fullchai Power and Yuanlin Co. have also seen consecutive trading gains, indicating strong market performance [3] - The company Guangxin Technology is a leader in optical modules and has partnered with Cisco to launch a 1.6T silicon optical module [3] Group 3 - The domestic automotive sector is witnessing significant developments, with China FAW planning to acquire approximately 10% of Leap Motor [6] - Companies like Mould Technology and Shentong Express are also making strides, with Mould Technology providing components for new energy vehicles [6] - The automotive thermal management sector is led by companies like Hanzhong Precision Machinery, which specializes in compressors and refrigeration products [8] Group 4 - The pharmaceutical industry is seeing a surge in domestic innovative drugs going global, with Tianmu Pharmaceutical being the first listed company in traditional Chinese medicine [7] - Companies like Huahai Pharmaceutical are advancing in the development of innovative drugs, with over 20 projects currently in research [7] - The automotive passive safety system sector is represented by companies like Songyuan Safety, which reported a 30.85% year-on-year increase in net profit [7]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，根据国家药品监督管理局药品审评中心（以下简称"CDE"）发布的公示信息，浙江华海药业股份 有限公司（以下简称"华海药业"或"公司"）下属子公司上海华奥泰生物药业股份有限公司（以下简 称"华奥泰"）自主研发的瑞西奇拜单抗（研发代号为：HB0034）注射液被纳入优先审评审批程序的品 种名单。根据《国家药监局关于发布突破性治疗药物审评工作程序（试行）等三个文件的公告》（2020 年第82号）有关要求，CDE对纳入优先审评审批程序的药品上市许可申请，按注册申请受理时间顺序优 先配置资源进行审评。现将相关情况公告如下： 一、药物基本情况 药物名称：瑞西奇拜单抗注射液 剂型：注射剂 拟定适应症：用于治疗成人泛发性脓疱型银屑病（GPP）发作 注册分类：治疗用生物制品1类 申请人：上海华奥泰生物药业股份有限公司 优先审评理由：本品符合《药品注册管理办法》和《国家药监局关于发布突破性治疗药物审评工作程序 （试行）等三个文件的公告》（20 ...

每经AI快讯，8月18日，华海药业(600521.SH)公告称，公司下属子公司华奥泰自主研发的瑞西奇拜单抗 （研发代号为：HB0034）注射液被纳入优先审评审批程序的品种名单。该药物用于治疗成人泛发性脓 疱型银屑病（GPP）发作，属于治疗用生物制品1类。目前全球范围内，尚未有国内企业自研的靶向IL- 36R抗体获批上市。HB0034作为国内首个自研创新抗IL-36R抗体，可通过抑制IL-36通路发挥抗炎的生 物学效应。 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 2025-090 | | --- | --- | --- | | | | 号 | | 债券简称：华海转债 | 债券代码：110076 | | 关于下属子公司产品被纳入优先审评品种名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，根据国家药品监督管理局药品审评中心（以下简称"CDE"）发布的公示 信息，浙江华海药业股份有限公司（以下简称"华海药业"或"公司"）下属子公司 上海华奥泰生物药业股份有限公司（以下简称"华奥泰"）自主研发的瑞西奇拜单抗 （研发代号为：HB0034）注射液被纳入优先审评审批程序的品种名单。根据《国家 药监局关于发布突破性治疗药物审评工作程序（试行）等三个文件的公告》（2020 年 第 82 号）有关要求，CDE 对纳入优先审评审批程序的药品上市许可申请，按注册申 请受理时间顺序优先配置资源进行审评。现将相关情况公告如下： 一、药物基本情况 药物名称：瑞西奇拜单抗注射液 剂型：注射剂 拟定适应症：用于治疗成人泛发性脓 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has decided not to lower the conversion price of its convertible bonds, Huahai Convertible Bonds, despite the stock price falling below the threshold for adjustment [1][4][14]. Group 1: Board Meeting and Decisions - The third temporary meeting of the ninth board of directors was held on August 15, 2025, with all nine directors present, meeting the legal requirements for the meeting [1]. - The board unanimously approved the proposal not to lower the conversion price of the Huahai Convertible Bonds [1][4]. Group 2: Convertible Bond Details - As of August 15, 2025, the company's stock price had been below 80% of the current conversion price for at least 15 trading days within any 30 consecutive trading days, triggering the adjustment clause [4][13]. - The initial conversion price was set at 34.66 CNY per share, with the latest conversion price adjusted to 33.06 CNY per share [5][9]. - The company issued 18.426 million convertible bonds with a total amount of 1.8426 billion CNY, with a maturity of six years from the issuance date [5]. Group 3: Future Considerations - The board will not propose a downward adjustment for the conversion price in the next two months (from August 16 to October 15, 2025), even if the adjustment clause is triggered again [4][14]. - Starting from October 16, 2025, if the adjustment clause is triggered again, the board will convene to consider whether to exercise the right to adjust the conversion price [5][14].